Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors
dc.contributor.author | Bode M.L. | |
dc.contributor.author | Gravestock D. | |
dc.contributor.author | Moleele S.S. | |
dc.contributor.author | Van Der Westhuyzen C.W. | |
dc.contributor.author | Pelly S.C. | |
dc.contributor.author | Steenkamp P.A. | |
dc.contributor.author | Hoppe H.C. | |
dc.contributor.author | Khan T. | |
dc.contributor.author | Nkabinde L.A. | |
dc.date.accessioned | 2011-10-13T16:58:53Z | |
dc.date.available | 2011-10-13T16:58:53Z | |
dc.date.issued | 2011 | |
dc.description.abstract | During random screening of a small in-house library of compounds, certain substituted imidazo[1,2-a]pyridines were found to be weak allosteric inhibitors of HIV-1 reverse transcriptase (RT). A library of these compounds was prepared using the Groebke reaction and a subset of compounds prepared from 2-chlorobenzaldehyde, cyclohexyl isocyanide and a 6-substituted 2-aminopyridine showed good inhibitory activity in enzymatic (RT) and HIV anti-infectivity MAGI whole cell assays. The compound showing the best anti-HIV-1 IIIB whole cell activity (MAGI IC50 = 0.18 μM, IC90 = 1.06 μM), along with a good selectivity index (>800), was 2-(2-chlorophenyl)-3- (cyclohexylamino)imidazo[1,2-a]pyridine-5-carbonitrile 38. © 2011 Elsevier Ltd. All rights reserved. | |
dc.description.version | Article | |
dc.identifier.citation | Bioorganic and Medicinal Chemistry | |
dc.identifier.citation | 19 | |
dc.identifier.citation | 14 | |
dc.identifier.citation | http://www.scopus.com/inward/record.url?eid=2-s2.0-79960004985&partnerID=40&md5=e71ae92d4cdeee251cfe3f87290495f1 | |
dc.identifier.issn | 9680896 | |
dc.identifier.other | 10.1016/j.bmc.2011.05.062 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/16894 | |
dc.subject | Antiretroviral | |
dc.subject | Groebke reaction | |
dc.subject | HIV | |
dc.subject | Imidazo[1,2-a]pyridine | |
dc.subject | NNRTI | |
dc.subject | Reverse transcriptase | |
dc.subject | 2 (2 bromophenyl) n cyclohexylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | 2 (2 chlorophenyl) 3 (cyclohexylamino)imidazo[1,2 a]pyridine 5 carbonitrile | |
dc.subject | 2 (2 chlorophenyl) n cyclohexylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | 2 (3 bromophenyl) n cyclohexylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | 2 (3 chlorophenyl) n cyclohexylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | 2 (4 bromophenyl) n cyclohexylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | 2 (4 chlorophenyl) n cyclohexylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | 2 aminopyridine derivative | |
dc.subject | 2 chlorobenzaldehyde | |
dc.subject | 2 sec butyl n cyclohexylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | cyclohexyl isocyanide | |
dc.subject | etravirine | |
dc.subject | imidazo[1,2 a]pyridine amine derivative | |
dc.subject | isopropyl n (pentan 2 yl)imidazo[1,2 a]pyridin 3 amine | |
dc.subject | isopropyl n pentylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | n butyl 2 isopropylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclohexyl 2 (2 fluorophenyl)imidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclohexyl 2 (4 fluorophenyl)imidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclohexyl 2 [2 (trifluorophenyl)phenyl]imidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclohexyl 2 [4 (trifluorophenyl)phenyl]imidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclohexyl 2 cyclopropylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclohexyl 2 isopropylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclohexyl 2 octylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclohexyl 2 phenylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | n cyclopentyl 2 isopropylimidazo[1,2 a]pyridin 3 amine | |
dc.subject | nonnucleoside reverse transcriptase inhibitor | |
dc.subject | reagent | |
dc.subject | rilpivirine | |
dc.subject | RNA directed DNA polymerase | |
dc.subject | unclassified drug | |
dc.subject | unindexed drug | |
dc.subject | antiviral activity | |
dc.subject | article | |
dc.subject | controlled study | |
dc.subject | drug selectivity | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | drug targeting | |
dc.subject | enzyme inhibition | |
dc.subject | IC 50 | |
dc.subject | molecular model | |
dc.subject | solvent effect | |
dc.subject | Human immunodeficiency virus 1 | |
dc.title | Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors | |
dc.type | Article |